These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 9789356)

  • 1. [Therapy of unstable angina pectoris. Thrombocyte aggregation inhibition improves chances for survival].
    Z Kardiol; 1998 Aug; 87(8 Suppl Thrombozy):1-3. PubMed ID: 9789356
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glycoprotein IIb/IIIa blockers. Their usefulness in current cardiovascular therapeutics].
    López Cuéllar J
    Arch Inst Cardiol Mex; 1999; 69(3):272-81. PubMed ID: 10529862
    [No Abstract]   [Full Text] [Related]  

  • 4. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 5. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    Mehta SR;
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microvascular obstruction in acute coronary syndromes: onward to a new therapeutic target.
    Schwartz RS
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):170-2. PubMed ID: 16142803
    [No Abstract]   [Full Text] [Related]  

  • 7. Unstable angina: the breakthrough.
    Hamm CW
    Eur Heart J; 1999 Nov; 20(21):1517-9. PubMed ID: 10529314
    [No Abstract]   [Full Text] [Related]  

  • 8. Different benefits, different risks, equal cost.
    Colombo A
    Eur Heart J; 1999 Nov; 20(21):1531-2. PubMed ID: 10529320
    [No Abstract]   [Full Text] [Related]  

  • 9. Abciximab and percutaneous coronary intervention: new indications. Medium-term benefit.
    Prescrire Int; 2000 Apr; 9(46):36-8. PubMed ID: 11503782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CAPTURE trial.
    Umans VA; Kloeg PH; Bronzwaer J
    Lancet; 1997 Aug; 350(9075):445. PubMed ID: 9259679
    [No Abstract]   [Full Text] [Related]  

  • 11. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications.
    Mayer DM; Docktor WJ
    Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118
    [No Abstract]   [Full Text] [Related]  

  • 12. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'.
    Montalescot G
    Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 15. Unstable angina: integrating new treatments.
    Schulman SP
    Hosp Pract (1995); 1997 Oct; 32(10):139-42, 144, 146-50. PubMed ID: 9341639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the use of abciximab in percutaneous coronary intervention.
    Iversen AZ
    Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [MULTISTRATEGY and FATA: merits, limits and troubles of no profit clinical trials in acute myocardial infarction].
    Savonitto S
    G Ital Cardiol (Rome); 2009 Jun; 10(6):364-5. PubMed ID: 19603607
    [No Abstract]   [Full Text] [Related]  

  • 19. Regimen lowers rate of coronary events in diabetes.
    Husten L
    Lancet; 1998 Aug; 352(9129):711. PubMed ID: 9728999
    [No Abstract]   [Full Text] [Related]  

  • 20. CD40 ligand--assessing risk instead of damage?
    Freedman JE
    N Engl J Med; 2003 Mar; 348(12):1163-5. PubMed ID: 12646674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.